Advertisement
Advertisement
SPRO
Spero Therapeutics, Inc. Common Stock
1.26
USDSponsored
-0.01
-0.79%
Aug 07, 15:54 UTC -4
Closed
Pre-Market
1.24
-0.02
-1.59%
SPRO Earnings Reports
Positive Surprise Ratio
SPRO beat 23 of 35 last estimates.
66%
Next Report
In 2 Days
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.17
Implied change from Q1 26 (Revenue/ EPS)
--
/+30.77%
Implied change from Q2 25 (Revenue/ EPS)
--
/+466.67%
Spero Therapeutics, Inc. Common Stock earnings per share and revenue
On May 13, 2026, SPRO reported earnings of -0.13 USD per share (EPS) for Q1 26, beating the estimate of -0.18 USD, resulting in a 29.19% surprise. Revenue reached 260.00 thousand, compared to an expected --, with a --% difference. The market reacted with a +13.11% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.17 USD, with revenue projected to reach -- USD, implying an increase of 30.77% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
Edgewise Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.53
Surprise
-10.55%
Denali Therapeutics Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.66
Actual
-$0.68
Surprise
-1.51%
Celldex Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.07
Actual
-$0.94
Surprise
+12.79%
FAQ
What were Spero Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Spero Therapeutics, Inc. Common Stock reported EPS of -$0.13, beating estimates by 29.19%, and revenue of $260.00K, -- -- expectations.
How did the market react to Spero Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 13.11%, changed from $2.44 before the earnings release to $2.76 the day after.
When is Spero Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Spero Therapeutics, Inc. Common Stock's next earnings report?
Based on 3
analysts, Spero Therapeutics, Inc. Common Stock is expected to report EPS of -$0.17 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement